Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series D round brings €65mm to Ganymed

Executive Summary

Cancer-focused Ganymed Pharmaceuticals raised €65mm ($82mm) in its Series D venture round. ATS Beteiligungsverwaltung GMBH led and was joined by Future Capital, MIG Verwaltungs AG, and private investors. Funds will be used to continue developing various preclinical solid tumor drug candidates.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies